Sulfamethoxazole-Trimethoprim Should Be Avoided During Pregnancy
Sulfamethoxazole-trimethoprim (co-trimoxazole) is not safe for routine use during pregnancy and should be avoided, particularly during the first and third trimesters. The FDA explicitly contraindicates this medication in pregnant patients, and multiple high-quality guidelines consistently recommend against its use due to significant fetal risks 1.
FDA Contraindication and Drug Label Evidence
The FDA drug label provides the most authoritative guidance: co-trimoxazole is contraindicated in pregnant patients because sulfonamides cross the placenta and may cause kernicterus in neonates 1. The medication is classified as Pregnancy Category C, with animal studies showing teratologic effects including cleft palates at high doses 1. While retrospective human data from Brumfitt and Pursell showed no abnormalities in limited cases, the FDA emphasizes that the drug should only be used "if the potential benefit justifies the potential risk to the fetus" 1.
Trimester-Specific Risks
First Trimester (T1)
- Avoid completely 2, 3
- Associated with increased risk of spontaneous abortion (adjusted OR 2.94,95% CI 1.89-4.57) 4
- Trimethoprim interferes with folic acid metabolism during critical organogenesis 2
- If trimethoprim exposure occurs, 5 mg/day folic acid supplementation is recommended 2
Second Trimester (T2)
- Possibly safe but not preferred 2
- Use only when safer alternatives are unavailable
- Continue folic acid supplementation if used
Third Trimester (T3) and at Delivery
- Avoid, especially near delivery 2
- Sulfonamide use associated with:
Recent Research Evidence
The most recent 2025 randomized controlled trial from Zimbabwe (n=993 pregnant women) found that trimethoprim-sulfamethoxazole prophylaxis during pregnancy did not significantly improve birth outcomes, with mean birth weight difference of only 20g (95% CI -43 to 83; P=0.53) 6. This challenges any potential benefit while the risks remain documented.
A 2026 preclinical study demonstrated that co-trimoxazole induces reproductive toxicity, reduces litter size, compromises placental barrier integrity, and disrupts cell-cell junctions through ERK pathway activation 7. This provides mechanistic evidence for the observed clinical harms.
Safer Antibiotic Alternatives During Pregnancy
When systemic antibiotics are needed in pregnancy, use these safer options instead 3:
First-line choices:
- Cephalexin (conditional recommendation, moderate quality evidence)
- Azithromycin (conditional recommendation, moderate quality evidence)
- Clindamycin (conditional recommendation, moderate quality evidence)
- Amoxicillin (compatible throughout pregnancy)
For urinary tract infections specifically 8:
- Fosfomycin trometamol (3g single dose)
- Nitrofurantoin (avoid near term due to hemolysis risk in newborn)
- Pivmecillinam
- Cephalosporins (cefadroxil, cefpodoxime)
Critical Clinical Pitfalls
- Do not use co-trimoxazole as first-line therapy when safer alternatives exist, even if local resistance patterns favor it
- Do not assume "possibly safe in T2" means recommended - this reflects lack of absolute contraindication, not safety endorsement
- Do not forget folic acid supplementation (5 mg/day) if inadvertent first-trimester exposure occurs 2
- Do not use near delivery due to kernicterus risk 1
Breastfeeding Considerations
Co-trimoxazole is compatible with breastfeeding only in healthy, full-term babies 2. Avoid in infants who are:
- Glucose-6-phosphate dehydrogenase (G6PD) deficient
- Jaundiced
- Premature
Both sulfamethoxazole and trimethoprim are distributed into breast milk 9, 1.
When Co-trimoxazole Might Be Considered (Rare Exceptions)
The only scenario where co-trimoxazole use might be justified is life-threatening maternal infection where no safer alternative exists and the benefit clearly outweighs fetal risk 1. This would require:
- Documented bacterial resistance to all safer alternatives
- Severe, life-threatening maternal infection
- Informed consent discussion about fetal risks
- Folic acid supplementation (5 mg/day)
- Avoidance of use at delivery if possible
The 2020 ERS/TSANZ respiratory guidelines and 2025 North American HS guidelines both explicitly recommend avoiding co-trimoxazole in pregnancy 2, 3, reinforcing that safer alternatives should always be prioritized.